{
  "total_claims_found": 25,
  "transcript_summary": "Johnson & Johnson reported strong Q2 2025 results with operational sales growth of 4.6% and raised its full-year guidance, despite headwinds from loss of exclusivity for STELARRA.",
  "claims": [
    {
      "is_approximate": false,
      "quote_start_char": 1001,
      "quote_end_char": 1090,
      "quote_text": "In the second quarter, we delivered operational sales growth of 4.6% across our business.",
      "unit": "percent",
      "metric_context": "Total",
      "claimed_value": 4.6,
      "claim_type": "yoy_growth",
      "gaap_classification": "non_gaap",
      "confidence": 1,
      "claim_id": "claim_001",
      "claimed_value_raw": "4.6%",
      "period": "Q2 2025",
      "metric_type": "revenue",
      "comparison_period": "Q2 2024"
    },
    {
      "quote_text": "In innovative medicine, we reported 3.8% operational sales growth, delivering more than $15 billion in quarterly sales for the first time.",
      "confidence": 1,
      "unit": "percent",
      "quote_start_char": 1091,
      "metric_type": "revenue",
      "is_approximate": false,
      "period": "Q2 2025",
      "claim_id": "claim_002",
      "claim_type": "yoy_growth",
      "gaap_classification": "non_gaap",
      "quote_end_char": 1229,
      "claimed_value": 3.8,
      "metric_context": "Innovative Medicine",
      "claimed_value_raw": "3.8%",
      "comparison_period": "Q2 2024"
    },
    {
      "claim_type": "yoy_growth",
      "quote_text": "Delivering 6.1% operational sales growth",
      "period": "Q2 2025",
      "claimed_value_raw": "6.1%",
      "unit": "percent",
      "metric_type": "revenue",
      "claimed_value": 6.1,
      "claim_id": "claim_004",
      "quote_start_char": 1627,
      "gaap_classification": "non_gaap",
      "metric_context": "MedTech",
      "is_approximate": false,
      "confidence": 1,
      "quote_end_char": 1667,
      "comparison_period": "Q2 2024"
    },
    {
      "metric_context": "Total",
      "claim_id": "claim_005",
      "claim_type": "guidance",
      "period": "FY 2025",
      "gaap_classification": "gaap",
      "unit": "dollars",
      "qualifiers": [
        "raise"
      ],
      "claimed_value": 2,
      "metric_type": "revenue",
      "quote_end_char": 1906,
      "quote_text": "Based on our strong performance in the quarter, we are pleased to raise our full-year sales guidance by $2 billion and EPS guidance by $0.25 from $10.60 to $10.85.",
      "claimed_value_raw": "$2 billion",
      "is_approximate": false,
      "scale": "billions",
      "quote_start_char": 1743,
      "confidence": 1
    },
    {
      "claim_id": "claim_006",
      "is_approximate": false,
      "metric_context": "Total",
      "period": "FY 2025",
      "quote_text": "Based on our strong performance in the quarter, we are pleased to raise our full-year sales guidance by $2 billion and EPS guidance by $0.25 from $10.60 to $10.85.",
      "quote_end_char": 1906,
      "claimed_value_raw": "$10.85",
      "claim_type": "guidance",
      "confidence": 1,
      "unit": "per_share",
      "qualifiers": [
        "raise"
      ],
      "quote_start_char": 1743,
      "gaap_classification": "non_gaap",
      "metric_type": "eps_diluted",
      "claimed_value": 10.85
    },
    {
      "metric_context": "Oncology",
      "quote_start_char": 3013,
      "period": "Q2 2025",
      "gaap_classification": "non_gaap",
      "claimed_value": 22.3,
      "confidence": 1,
      "is_approximate": false,
      "metric_type": "revenue",
      "unit": "percent",
      "quote_end_char": 3167,
      "claimed_value_raw": "22.3%",
      "claim_id": "claim_007",
      "claim_type": "yoy_growth",
      "quote_text": "And when you look at our quarterly results in oncology, with operational sales growth of 22.3%, you can see that we are well on our way to achieving that.",
      "comparison_period": "Q2 2024"
    },
    {
      "claim_type": "yoy_growth",
      "claimed_value_raw": "30%",
      "quote_text": "TREMFYA grew 30% in the quarter.",
      "metric_context": "TREMFYA",
      "quote_end_char": 5532,
      "unit": "percent",
      "metric_type": "revenue",
      "gaap_classification": "gaap",
      "confidence": 1,
      "period": "Q2 2025",
      "quote_start_char": 5500,
      "claimed_value": 30,
      "claim_id": "claim_008",
      "is_approximate": false,
      "comparison_period": "Q2 2024"
    },
    {
      "unit": "percent",
      "is_approximate": false,
      "claim_id": "claim_009",
      "quote_end_char": 6364,
      "claim_type": "yoy_growth",
      "period": "Q2 2025",
      "gaap_classification": "gaap",
      "metric_context": "SPRAVATO",
      "claimed_value_raw": "53%",
      "quote_text": "In Q2, SPRAVATO grew 53%",
      "claimed_value": 53,
      "quote_start_char": 6340,
      "metric_type": "revenue",
      "confidence": 1,
      "comparison_period": "Q2 2024"
    },
    {
      "quote_end_char": 7572,
      "quote_start_char": 7398,
      "metric_type": "revenue",
      "claim_type": "yoy_growth",
      "claimed_value": 22,
      "confidence": 1,
      "claimed_value_raw": "22%",
      "quote_text": "In Q2, we delivered over 22% operational sales growth over the quarter, driven by new product performance in Abiomed, Shockwave, and strength in mapping in electrophysiology.",
      "qualifiers": [
        "over"
      ],
      "claim_id": "claim_010",
      "unit": "percent",
      "period": "Q2 2025",
      "is_approximate": false,
      "gaap_classification": "non_gaap",
      "metric_context": "Cardiovascular",
      "comparison_period": "Q2 2024"
    },
    {
      "confidence": 1,
      "period": "Q2 2025",
      "qualifiers": [
        "close to"
      ],
      "claim_type": "yoy_growth",
      "quote_end_char": 7966,
      "gaap_classification": "non_gaap",
      "is_approximate": true,
      "metric_type": "revenue",
      "claim_id": "claim_011",
      "claimed_value_raw": "10%",
      "unit": "percent",
      "claimed_value": 10,
      "quote_text": "First is electrophysiology, which delivered close to 10% operational sales growth over the quarter, driven by new product performance and strength in mapping.",
      "metric_context": "Electrophysiology",
      "quote_start_char": 7808,
      "comparison_period": "Q2 2024"
    },
    {
      "quote_end_char": 10507,
      "quote_start_char": 10260,
      "metric_type": "revenue",
      "claim_type": "yoy_growth",
      "confidence": 1,
      "gaap_classification": "gaap",
      "period": "Q2 2025",
      "unit": "percent",
      "claim_id": "claim_012",
      "is_approximate": false,
      "claimed_value": 8.9,
      "quote_text": "With quarterly growth of 4.6% across the business and 8.9% in Surgical Vision, the portfolio has a robust growth trajectory driven by our Acuvue OASYS MAX 1-Day family of contact lenses and our TECNIS Eyhance and TECNIS Synergy intraocular lenses.",
      "claimed_value_raw": "8.9%",
      "metric_context": "Surgical Vision",
      "comparison_period": "Q2 2024"
    },
    {
      "is_approximate": false,
      "gaap_classification": "gaap",
      "claimed_value": 23.7,
      "scale": "billions",
      "quote_start_char": 11569,
      "period": "Q2 2025",
      "claim_id": "claim_013",
      "claim_type": "absolute",
      "confidence": 1,
      "metric_context": "Total",
      "unit": "dollars",
      "quote_text": "Worldwide sales were $23.7 billion for the quarter.",
      "metric_type": "revenue",
      "quote_end_char": 11620,
      "claimed_value_raw": "$23.7 billion"
    },
    {
      "claimed_value_raw": "$5.5 billion",
      "claimed_value": 5.5,
      "scale": "billions",
      "unit": "dollars",
      "quote_end_char": 12051,
      "quote_text": "For the quarter, net earnings were $5.5 billion with diluted earnings per share of $2.29 versus diluted earnings per share of $1.93 a year ago.",
      "quote_start_char": 11908,
      "metric_context": "Total",
      "period": "Q2 2025",
      "confidence": 1,
      "claim_type": "absolute",
      "claim_id": "claim_014",
      "is_approximate": false,
      "gaap_classification": "gaap",
      "metric_type": "net_income"
    },
    {
      "claim_type": "absolute",
      "claimed_value_raw": "$2.29",
      "claimed_value": 2.29,
      "unit": "per_share",
      "is_approximate": false,
      "quote_end_char": 12051,
      "metric_context": "Total",
      "quote_start_char": 11908,
      "metric_type": "eps_diluted",
      "confidence": 1,
      "claim_id": "claim_015",
      "quote_text": "For the quarter, net earnings were $5.5 billion with diluted earnings per share of $2.29 versus diluted earnings per share of $1.93 a year ago.",
      "period": "Q2 2025",
      "gaap_classification": "gaap"
    },
    {
      "claimed_value_raw": "$2.77",
      "claim_type": "absolute",
      "gaap_classification": "non_gaap",
      "metric_context": "Total",
      "period": "Q2 2025",
      "quote_end_char": 12254,
      "unit": "per_share",
      "quote_start_char": 12053,
      "claim_id": "claim_016",
      "confidence": 1,
      "quote_text": "Adjusted net earnings for the quarter were $6.7 billion with adjusted diluted earnings per share of $2.77, representing a decrease of 2.1% and 1.8% respectively, compared to the second quarter of 2024.",
      "metric_type": "eps_diluted",
      "claimed_value": 2.77,
      "is_approximate": false
    },
    {
      "claimed_value_raw": "$15.2 billion",
      "claimed_value": 15.2,
      "quote_start_char": 12693,
      "claim_type": "absolute",
      "scale": "billions",
      "gaap_classification": "gaap",
      "confidence": 1,
      "is_approximate": false,
      "unit": "dollars",
      "period": "Q2 2025",
      "quote_end_char": 12740,
      "metric_type": "revenue",
      "claim_id": "claim_017",
      "metric_context": "Innovative Medicine",
      "quote_text": "Worldwide sales of $15.2 billion increased 3.8%"
    },
    {
      "claim_id": "claim_018",
      "claim_type": "yoy_growth",
      "quote_text": "DARZALEX growth was 21.5%",
      "claimed_value": 21.5,
      "is_approximate": false,
      "quote_end_char": 13219,
      "claimed_value_raw": "21.5%",
      "confidence": 1,
      "unit": "percent",
      "gaap_classification": "gaap",
      "metric_context": "DARZALEX",
      "metric_type": "revenue",
      "quote_start_char": 13194,
      "period": "Q2 2025",
      "comparison_period": "Q2 2024"
    },
    {
      "period": "Q2 2025",
      "quote_start_char": 13402,
      "metric_type": "revenue",
      "quote_end_char": 13513,
      "quote_text": "CARVICTI achieved sales of $439 million with growth of over 100%, driven by share gains and capacity expansion.",
      "confidence": 1,
      "scale": "millions",
      "claim_id": "claim_019",
      "claim_type": "absolute",
      "claimed_value": 439,
      "is_approximate": false,
      "gaap_classification": "gaap",
      "unit": "dollars",
      "claimed_value_raw": "$439 million",
      "metric_context": "CARVICTI"
    },
    {
      "claimed_value": 17.9,
      "quote_end_char": 13603,
      "quote_text": "This reflects continued strong sequential growth of 17.9% as we expand outside of the US.",
      "metric_type": "revenue",
      "claim_id": "claim_020",
      "claim_type": "qoq_growth",
      "gaap_classification": "gaap",
      "is_approximate": false,
      "quote_start_char": 13514,
      "unit": "percent",
      "confidence": 1,
      "period": "Q2 2025",
      "claimed_value_raw": "17.9%",
      "metric_context": "CARVICTI",
      "comparison_period": "Q1 2025"
    },
    {
      "quote_end_char": 14085,
      "claim_type": "absolute",
      "confidence": 1,
      "claim_id": "claim_021",
      "scale": "millions",
      "is_approximate": false,
      "quote_text": "In lung cancer, RYBREVANT plus LUMAKRAS delivered sales of $179 million and growth over 100%, with sequential growth of 26.5% driven by continued strong launch uptake.",
      "metric_type": "revenue",
      "period": "Q2 2025",
      "metric_context": "RYBREVANT plus LUMAKRAS",
      "quote_start_char": 13918,
      "gaap_classification": "gaap",
      "claimed_value_raw": "$179 million",
      "unit": "dollars",
      "claimed_value": 179
    },
    {
      "claimed_value": 8.5,
      "quote_text": "Worldwide sales of $8.5 billion increased 6.1%",
      "scale": "billions",
      "period": "Q2 2025",
      "unit": "dollars",
      "metric_context": "MedTech",
      "quote_start_char": 14736,
      "confidence": 1,
      "quote_end_char": 14782,
      "claimed_value_raw": "$8.5 billion",
      "metric_type": "revenue",
      "is_approximate": false,
      "gaap_classification": "gaap",
      "claim_type": "absolute",
      "claim_id": "claim_022"
    },
    {
      "quote_text": "We continued our strong investment in research and development, with $3.5 billion or approximately 15% of sales in Q2.",
      "metric_context": "Total",
      "claim_type": "absolute",
      "quote_start_char": 17006,
      "period": "Q2 2025",
      "confidence": 1,
      "quote_end_char": 17124,
      "is_approximate": false,
      "gaap_classification": "gaap",
      "scale": "billions",
      "claimed_value_raw": "$3.5 billion",
      "unit": "dollars",
      "claimed_value": 3.5,
      "metric_type": "research_and_development",
      "claim_id": "claim_023"
    },
    {
      "claimed_value": 6,
      "claimed_value_raw": "$6 billion",
      "claim_type": "absolute",
      "scale": "billions",
      "metric_context": "Total",
      "quote_text": "Free cash flow through the first half of 2025 exceeded $6 billion, which accounts for elevated tax payments related to the final annual TCJA toll tax payment when compared to the first half of 2024.",
      "claim_id": "claim_024",
      "confidence": 1,
      "gaap_classification": "unknown",
      "period": "H1 2025",
      "unit": "dollars",
      "quote_end_char": 20469,
      "is_approximate": false,
      "metric_type": "free_cash_flow",
      "quote_start_char": 20271,
      "qualifiers": [
        "exceeded"
      ]
    },
    {
      "quote_text": "We are now expecting operational sales growth for the full year to be in the range of 4.5% to 5%, with a midpoint of $92.9 billion or 4.8%, representing a full point better when compared to prior guidance.",
      "quote_end_char": 21367,
      "is_approximate": false,
      "claim_id": "claim_025",
      "scale": "billions",
      "claimed_value": 92.9,
      "confidence": 1,
      "unit": "dollars",
      "claimed_value_raw": "$92.9 billion",
      "period": "FY 2025",
      "metric_context": "Total",
      "quote_start_char": 21162,
      "metric_type": "revenue",
      "gaap_classification": "non_gaap",
      "claim_type": "guidance"
    }
  ],
  "ticker": "JNJ",
  "year": 2025,
  "quarter": 2,
  "extracted_at": "2026-02-13T17:37:47.632957"
}